PL2114419T3 - Metaarsenin sodu do stosowania w leczeniu bólu i zapalenia - Google Patents

Metaarsenin sodu do stosowania w leczeniu bólu i zapalenia

Info

Publication number
PL2114419T3
PL2114419T3 PL08714162T PL08714162T PL2114419T3 PL 2114419 T3 PL2114419 T3 PL 2114419T3 PL 08714162 T PL08714162 T PL 08714162T PL 08714162 T PL08714162 T PL 08714162T PL 2114419 T3 PL2114419 T3 PL 2114419T3
Authority
PL
Poland
Prior art keywords
inflammation
pain
treatment
sodium meta
meta arsenite
Prior art date
Application number
PL08714162T
Other languages
English (en)
Inventor
Michael Hwang
Yong-Jin Yang
Original Assignee
Panaphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panaphix Inc filed Critical Panaphix Inc
Publication of PL2114419T3 publication Critical patent/PL2114419T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
PL08714162T 2007-02-02 2008-02-01 Metaarsenin sodu do stosowania w leczeniu bólu i zapalenia PL2114419T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89900707P 2007-02-02 2007-02-02
US12/068,006 US8945505B2 (en) 2007-02-02 2008-01-31 Use of arsenic compounds for treatment of pain and inflammation
PCT/US2008/052751 WO2008097824A2 (en) 2007-02-02 2008-02-01 Use of arsenic compounds for treatment of pain and inflammation
EP08714162.8A EP2114419B8 (en) 2007-02-02 2008-02-01 Sodium meta arsenite for use in the treatment of pain and inflammation

Publications (1)

Publication Number Publication Date
PL2114419T3 true PL2114419T3 (pl) 2014-10-31

Family

ID=39322911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08714162T PL2114419T3 (pl) 2007-02-02 2008-02-01 Metaarsenin sodu do stosowania w leczeniu bólu i zapalenia

Country Status (19)

Country Link
US (2) US8945505B2 (pl)
EP (1) EP2114419B8 (pl)
JP (3) JP5411709B2 (pl)
KR (1) KR101479519B1 (pl)
CN (2) CN103550253A (pl)
AR (1) AR065138A1 (pl)
AU (1) AU2008214084C9 (pl)
BR (1) BRPI0807154B8 (pl)
CA (3) CA2845292C (pl)
DK (1) DK2114419T3 (pl)
ES (1) ES2460868T3 (pl)
HK (1) HK1138512A1 (pl)
IL (3) IL200173A (pl)
MX (1) MX2009008174A (pl)
NZ (1) NZ578621A (pl)
PL (1) PL2114419T3 (pl)
RU (3) RU2468806C2 (pl)
TW (1) TWI404538B (pl)
WO (1) WO2008097824A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090061022A1 (en) * 2004-10-08 2009-03-05 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8045505B2 (en) * 2007-01-18 2011-10-25 Science Applications International Corporation Mechanism for automatic network formation and medium access coordination
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
EP2432480B1 (en) * 2009-05-18 2021-05-05 The University of Hong Kong Compositions and methods for treating inflammatory arthritis
EP2470207A1 (en) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
LT2475362T (lt) * 2009-09-10 2019-06-10 Kominox, Inc. Tikslinė vėžinių kamieninių ląstelių ir atsparaus vaistams vėžio terapija
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
CN106890353A (zh) * 2017-03-31 2017-06-27 应剑波 一种具有抗菌滋养功能的医用辅料
US10716807B2 (en) * 2017-05-09 2020-07-21 Medsenic Method of treating relapsing-remitting multiple sclerosis using arsenic trioxide
EP3768247A4 (en) * 2018-03-22 2021-12-29 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
RU2687599C1 (ru) * 2018-11-22 2019-05-15 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения постмастэктомического синдрома
CN109674817B (zh) * 2019-01-31 2021-06-29 哈尔滨医科大学 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途
WO2020234414A1 (en) * 2019-05-21 2020-11-26 Medsenic Use of metal ions to potentiate the therapeutic effects of arsenic
EP4103200A4 (en) * 2020-02-16 2023-08-16 Komipharm International Australia Pty Ltd METHOD OF TREATMENT USING META-ARSENITE
RU2755329C2 (ru) * 2020-03-13 2021-09-15 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ /ФГБУ "РНЦРХТ им. академика А.М. Гранова" Минздрава России Способ лечения нерезектабельной гилюсной холангиокарциномы
EP3988093A1 (en) * 2020-10-22 2022-04-27 Medsenic Use of an arsenic compound for treating a cytokine storm
CA3174032A1 (en) * 2020-04-03 2021-10-07 Francois Rieger Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
KR102240693B1 (ko) * 2020-05-18 2021-04-15 주식회사 케마스 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
US20220228142A1 (en) 2020-12-17 2022-07-21 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536273A (en) * 1895-03-26 Tavus rein
US1498639A (en) * 1919-12-02 1924-06-24 David S Pratt Arsenical composition and method of making same
US3622664A (en) * 1968-11-21 1971-11-23 John A Brown Treatment of infectious keratitis in animals with sodium arsenite
SU955909A1 (ru) * 1980-06-25 1982-09-07 Центральный Ордена Ленина Институт Усовершенствования Врачей Способ профилактики осложнений при пересадке тканей
US4677974A (en) * 1985-09-30 1987-07-07 David Leonardi Method and apparatus for immobilizing an eyelid
AU647822B2 (en) 1990-09-14 1994-03-31 Marion Merrell Dow Inc. Novel carbocyclic adenosine analogs useful as immunosuppressants
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
DE69434093T2 (de) 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
IT1272994B (it) * 1994-05-25 1997-07-01 Giampiero Valletta Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.-
IT1295067B1 (it) * 1997-09-25 1999-04-27 Walter Tarello Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
ATE409043T1 (de) 1997-10-15 2008-10-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von krebs des zentralen nervensystems
KR20020083678A (ko) 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI259079B (en) * 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
RU2310460C2 (ru) * 2002-04-10 2007-11-20 Корея Микробиолоджикал Лабораторис, Лтд. Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
EP2042182B1 (en) 2002-04-10 2013-05-22 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
JP2005206591A (ja) * 2003-12-25 2005-08-04 Mitsubishi Pharma Corp 神経因性疼痛の予防及び／又は治療のための医薬
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
JP2006206461A (ja) 2005-01-26 2006-08-10 Teizo Chinen アレルギー疾患の予防・治療用組成物
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases

Also Published As

Publication number Publication date
RU2012134218A (ru) 2014-02-20
BRPI0807154B8 (pt) 2021-05-25
JP2010518022A (ja) 2010-05-27
EP2114419B1 (en) 2014-04-09
CA2677388C (en) 2017-07-25
IL229255A (en) 2015-02-26
CA2845292A1 (en) 2008-08-14
AU2008214084C9 (en) 2014-04-03
CA2845299C (en) 2017-03-07
IL200173A (en) 2013-12-31
EP2114419B8 (en) 2014-06-11
MX2009008174A (es) 2009-11-26
CA2677388A1 (en) 2008-08-14
AU2008214084C1 (en) 2014-03-06
US8945505B2 (en) 2015-02-03
CA2845292C (en) 2017-09-12
IL229255A0 (en) 2013-12-31
BRPI0807154A2 (pt) 2014-04-22
WO2008097824A3 (en) 2009-03-26
JP5411709B2 (ja) 2014-02-12
BRPI0807154B1 (pt) 2021-01-12
TWI404538B (zh) 2013-08-11
DK2114419T3 (da) 2014-06-10
US10058570B2 (en) 2018-08-28
JP5853347B2 (ja) 2016-02-09
US20080193560A1 (en) 2008-08-14
JP5825611B2 (ja) 2015-12-02
WO2008097824A2 (en) 2008-08-14
RU2665362C2 (ru) 2018-08-29
US20130309319A1 (en) 2013-11-21
JP2015007138A (ja) 2015-01-15
RU2468806C2 (ru) 2012-12-10
IL200173A0 (en) 2010-04-15
JP2013147511A (ja) 2013-08-01
RU2009132951A (ru) 2011-03-10
AU2008214084B2 (en) 2013-10-31
KR101479519B1 (ko) 2015-01-08
CA2845299A1 (en) 2008-08-14
HK1138512A1 (en) 2010-08-27
AR065138A1 (es) 2009-05-20
NZ578621A (en) 2011-06-30
RU2013151904A (ru) 2015-05-27
CN101641105A (zh) 2010-02-03
RU2630574C2 (ru) 2017-09-11
IL217891A0 (en) 2012-03-29
KR20090122348A (ko) 2009-11-27
EP2114419A2 (en) 2009-11-11
AU2008214084A1 (en) 2008-08-14
IL217891A (en) 2014-05-28
TW200843734A (en) 2008-11-16
ES2460868T3 (es) 2014-05-14
CN103550253A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
HK1138512A1 (en) Sodium meta arsenite for use in the treatment of pain and inflammation
HRP20190059T1 (hr) Pripravci za liječenje boli i/ili upale
IL229975A (en) Sodium metas arsenite preparations for the treatment of pain and inflammation are associated with cancer
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
WO2008106102A9 (en) Inhibitors of rtp801 and their use in disease treatment
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP2173740A4 (en) INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
HK1203160A1 (en) Tapentadol for the treatment of pain in arthrosis (tapentadol)
HK1209053A1 (zh) 地來西坦在慢性疼痛的治療中的用途
EP2021005A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
HK1160471A1 (en) Aminophosphinic derivatives that can be used in the treatment of pain
IL207965A0 (en) N-substitutedbenzenepropanamide ofr denzenepropenamide derivatives for use in the treatment of pain and inflammation
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
HK1179523A1 (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation n-
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
EP1973398A4 (en) USE OF INOSITE TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
HK1201043A1 (en) Sodium meta arsenite for use in the treatment of pain and or inflammation associated with cancer
TWI340035B (en) Lemnalol applying for treating inflammation and pain
GB0705424D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome